Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2018’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections

- The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects

- The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

Abivax SA

Ablynx NV

ADMA Biologics Inc

Agilvax Inc

Amarillo Biosciences Inc

Anima Biotech Ltd

Aridis Pharmaceuticals Inc

Artificial Cell Technologies Inc ...

3-V Biosciences Inc

Abivax SA

Ablynx NV

ADMA Biologics Inc

Agilvax Inc

Amarillo Biosciences Inc

Anima Biotech Ltd

Aridis Pharmaceuticals Inc

Artificial Cell Technologies Inc

AstraZeneca Plc

Bavarian Nordic A/S

BlueWillow Biologics

Celltrion Inc

Curevac AG

DBV Technologies SA

Enanta Pharmaceuticals Inc

Evec Inc

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

GenVec Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

iBio Inc

Immunovaccine Inc

Immunwork Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

mAbxience SA

MedImmune LLC

Medivir AB

Navigen Inc

Novavax Inc

Phoenix Biotechnology Inc

Profectus BioSciences Inc

Pulmocide Ltd

ReViral Ltd

Romark Laboratories LC

TechnoVax Inc

Themis Bioscience GmbH

Vault Pharma Inc

Vaxart Inc

Virometix AG

Visterra Inc

VLP Biotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Respiratory Syncytial Virus (RSV) Infections – Overview 6

Respiratory Syncytial Virus (RSV) Infections – Therapeutics Development ...

Table of Contents

Table of Contents 2

Introduction 5

Respiratory Syncytial Virus (RSV) Infections – Overview 6

Respiratory Syncytial Virus (RSV) Infections – Therapeutics Development 7

Respiratory Syncytial Virus (RSV) Infections – Therapeutics Assessment 21

Respiratory Syncytial Virus (RSV) Infections – Companies Involved in Therapeutics Development 29

Respiratory Syncytial Virus (RSV) Infections – Drug Profiles 49

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects 213

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products 218

Respiratory Syncytial Virus (RSV) Infections – Product Development Milestones 219

Appendix 228

List of Tables

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2018

Number of Products under Development by Companies, H1 2018 ...

List of Tables

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by BlueWillow Biologics, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2018

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2018 (Contd..1), H1 2018

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2018 (Contd..2), H1 2018

Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, H1 2018 (Contd..3), H1 2018

Respiratory Syncytial Virus (RSV) Infections – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2018

Number of Products under Development by Companies, H1 2018 ...

List of Figures

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports